SLCO1B1 and Hyperbilirubinemia: In the study by Nakakariya et al. [79], the cut-off of IC50 ≤ 6 μM for OATP1B1 inhibition reliably identified compounds that cause hyperbilirubinemia at a frequency of ≥1%, although it was not specified whether these compounds induce accumulation of unconjugated or conjugated bilirubin.